drugset
drugset / Trial / NCT06201663

Romiplostim in Chemotherapy-Induced Thrombocytopenia

NCT06201663 ↗

Phase 3 Unknown 30 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelSupportive care

Summary

Prospective interventional randomized controlled trial to assess safety and efficacy of romiplostim in chemotherapy-induced thrombocytopenia in children and adolescents with solid malignancy

Timeline

Start
2023-12-17
Primary completion
2025-05
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Romiplostim Peptide 3 ug/kg Subcutaneous

Indications

cancer thrombocytopenia